John Buse, MD, PhD, division chief of endocrinology in the department of medicine, was featured on WRAL last week for his leadership role in a global clinical trial to assess the efficacy of a new type-2 diabetes drug called iDegLira, which is available in Europe but still under FDA review in the United States. It is a second-line therapy after metformin, the first line treatment for people with type-2 diabetes. Read more about this clinical study here.
This week, WRAL interviewed Dr. Buse about the three ways to screen for high blood sugar to diagnose type-2 diabetes. Watch the video.
John Buse, MD, PhD, is the director of the NC TraCS Institute, the academic home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC. He is also the director of the UNC Diabetes Care Center.